Introduction
Tongue squamous cell carcinoma (TSCC) is the most common oral cancer, accounting for 22–49% of all oral cancers [
1]. Tongue squamous cell carcinoma has a high degree of malignancy and rate of neck cervical metastasis with a relatively poor prognosis [
2,
3]. Nowadays, while surgery-based comprehensive treatment methods are generally adopted, surgical treatment programs usually cause defects of the tongue, which will seriously affect the quality of life in patients [
4]. The clinical manifestations of early TSCC are easily ignored by patients, which makes patients lose the best time for treatment [
5]. At present, it has been reported that the 5-year survival rate of TSCC is about 56.3% [
6], and the current clinical staging needs to be further improved to accurately predict the prognosis of patients.
Autophagy is a highly conserved catabolic process, which is widely distributed in eukaryotes [
7]. Under normal physiological conditions, autophagy eliminates dysfunctional organelles and misfolded proteins in the maintenance of cell homeostasis. Dysregulation for autophagy is associated with numerous diseases, such as cancer, metabolic diseases, pathogen infections, and neurodegenerative diseases [
8]. Increasing evidence demonstrates that autophagy has a dual role in cancer: autophagy promotes or suppresses the growth of cancer cells by regulating the effects of tumor drugs on cancer cells [
9,
10]. The key goal of discovering specific biomarkers of TSCC is to improve the quality of life for patients by early diagnosis and timely treatment. Three proteins, solute carrier family 3 member 2, S100 calcium‐binding protein A2, and IL‐1 receptor antagonist protein were expected to be used as biomarkers for early detection of OSCC. Recent evidence suggests that autophagy modulators may be a potential treatment for the biomarkers (such as protein, RNA, autoantibody and combined biomarkers) in TSCC [
11]. Therefore, autophagy-related biomarkers may play an essential role in the early diagnosis and prognosis prediction of TSCC.
Long non-coding RNA (lncRNA), which does not have the ability to encode proteins, plays an indispensable role in all levels of gene function and regulation. LncRNA has plenty of biological functions, for instance, cell proliferation, differentiation, metabolism of RNA, and regulation of epigenetics [
12]. Previous studies suggested that lncRNA mediates the expression of autophagy-related genes to coordinate signal pathways with autophagy [
13,
14]. Recent studies showed that overexpressed lncRNA CASC9 contributes to the progression of oral squamous cell carcinoma (OSCC) through autophagy-mediated apoptosis [
15].
Therefore, we utilized The Cancer Genome Atlas (TCGA) to comprehensively estimate the relationship between the autophagy-related lncRNA and clinicopathological characteristics of tongue squamous cell carcinoma. Because of autophagy-related lncRNA, a prognostic marker was established and its ability to independently predict the prognosis of tongue squamous cell carcinoma patients was evaluated.
Discussion
OSCC is the most common and main malignant tumor in head and neck cancer [
20]. The International Union Against Cancer has included OSCC as one of the most common malignant cancers, with approximately 275,000 cases worldwide each year [
21]. Oral TSCC is the main component of OSCC. Compared with other malignant tumors of the head and neck, tongue cancer has strong invasiveness, high metastasis and, high recurrence, which obviously affect the functions of chewing, swallowing, and breathing [
22]. Autophagy has been confirmed to be associated with the development of various cancers, including TSCC [
23]. Therefore, biomarkers related to autophagy may play an important role in the early diagnosis and targeted therapy of tongue cancer. Previous studies focused on the regulation of genes related to autophagy in TSCC [
24,
25].
More and more reports indicate that lncRNA, as a non-coding molecule, is closely related to autophagy in the malignant progression of some cancers [
26]. Therefore, lncRNA is a potential biomarker to predict the prognosis of tumor patients. As far as we know, there is no systematic method to identify the lncRNA signature used to predict the survival of TSCC patients. Therefore, this study established autophagy-related lncRNA signatures to accurately predict the prognosis of TSCC.
In this study, we first shortlisted lncRNAs related to autophagy in samples of TSCC patients from the TCGA database and identified 25 lncRNAs related to survival time through univariate Cox regression. The ten lncRNAs related to autophagy were identified via multivariate Cox regression analysis. In addition, based on the median risk score calculated by the expression level of lncRNA, the patients with TSCC were divided into high-risk and low-risk groups. There were significant statistical differences between high-risk and low-risk survival rates (p = 5.814e−08). The ROC curve confirms the accuracy of autophagy-related lncRNA prognostic signatures in TSCC patients (AUC = 0.782). We can conclude from univariate and multivariate Cox regression analysis that autophagy-related lncRNA prognostic signature is an independent prognostic factor significantly related to OS. In different clinical categories (such as gender, age, grade, AJCC stage, T stage, and N stage), autophagy-related lncRNA prognostic signatures can accurately predict the survival outcome of the different groups, indicating that this prognostic model is accurate and reliable.
Compared with traditional clinical features, autophagy-related lncRNA prognostic models are more accurate predictors. For many cancers, the nomogram is superior to the traditional TNM staging system because of its applicability and accuracy, so it has been proposed as an alternative or as a new standard [
27]. Therefore, based on current clinical information and autophagy-related lncRNA prognostic signatures, we developed a nomogram for TSCC. The calibration curve analysis shows that the actual 1-year and 3-year survival times are similar to the actual values of TSCC. To summarise, the autophagy-related lncRNA prognostic signatures we established have great potential for clinical application.
Autophagy is a highly conservative biological process to maintain cell metabolism. Under pathological or physiological conditions, autophagosomes captures and degrades intracellular components, such as proteins and organelles in lysosomes [
28]. The exact mechanism of autophagy in cancer has not yet been fully elucidated and the dual effects of autophagy on the inhibition and promotion of various tumors remain controversial [
29]. AMPK and mTOR negatively regulate tumor suppressor factors, leading to the induction of autophagy and tumor suppression in the early stage of cancer [
30]. On the other hand, oncogenes may be activated by class I PI3K, AKT, and mTOR, contributing to the inhibition of autophagy and the promotion of cancer [
31]. In recent years, there have been more studies about lncRNA that regulate autophagy to influence the biological behavior of OSCC [
32‐
36]. LncRNA HOTAIR accelerates the proliferation, migration, and invasion of OSCC cells by raising the expression of microtubule-associated protein 1 light chain 3B (MAP1LC3B), Beclin 1 (BECN1), autophagy-related gene (ATG3 and ATG7) [
37]. Yang et al. reported that lncRNA CASC9 was significantly up-regulated in OSCC. The knockout of CASC9 significantly reduced the expression level of p-mTOR, BCL-2, p-AKT, and P62, which demonstrated that lncRNA CASC9 suppresses autophagy-mediated apoptosis by AKT/mTOR pathway to promote OSCC progression [
15]. Therefore, we identified ten lncRNAs related to autophagy and constructed a lncRNA-mRNA co-expression network to evaluate their functions. The terms and pathways related to autophagy have been significantly enriched (
p < 0.05) in the functional analysis of GO, KEGG, and GSEA. It implies that autophagy plays a pivotal role in the progression of TSCC and might have a potential as a therapeutic target, which is consistent with previous studies [
38].
Our study has several limitations. First, the sample size of TSCC patients we obtained in the TCGA database is limited, which may affect the accuracy of the prognostic model we constructed. Second, the sample information based on the 7th edition AJCC classification is limited since the 8th edition AJCC has a better prognostic value than the 7th edition. Finally, our findings need to be further validated in other independent cohorts to determine the robustness of autophagy-related lncRNA prognostic signature.
In summary, the constructed autophagy-related lncRNA prognostic signature can accurately predict the prognosis of TSCC patients. A nomogram containing lncRNAs and other clinicopathological characteristics is established, and our research suggests that the nomogram could correctly predict the survival outcomes of TSCC patients. These ten lncRNAs are potential prognostic biomarkers and possible targets for TSCC treatment.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.